Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232 · RASolute 304 Phase 3Recruiting
- Lead sponsor
- Revolution Medicines, Inc. (Industry)
- Enrollment
- 500 (estimated)
- Start date
- 15 Dec 2025
- Primary completion
- 10 May 2029 (estimated)
- Study completion
- 10 Jul 2030
- Last update posted
- 23 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- daraxonrasib Drug
Conditions and primary outcome
- Pancreatic Cancer
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
- Resected Pancreatic Adenocarcinoma
Primary outcome
Disease-Free Survival (DFS) per Investigator (Up to approximately 5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07252232.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07252232 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.